Treatment of cutaneous T cell lymphoma
1 Views
administrator
08/09/23
Dr Duvic speaks with ecancertv at WCCS 2016 about mogamulizumab, an anti-CCR4 engineered antibody for treatment of cutaneous T cell lymphoma, also known as Sézary syndrome.
She reports on results from a phase I/II trial in which patient response rate reached 37%, and describes upcoming trials for mogamulizumab, with considerations of international approval and possible combination/complementary therapies.
-
Category
Show more
Facebook Comments
No comments found